Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
We’re delighted that NICE has approved bevacizumab for first- and second-line treatment in combination with chemotherapy for advanced bowel cancer patients in England and Wales, following a similar ...
Lifileucel for previously treated unresectable or metastatic melanoma ID3863 Draft guidance Technology appraisal guidance 22 January 2026 Filgotinib for treating axial spondyloarthritis ID6594 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback